YOLFTbeta
Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD · NASDAQ · Healthcare / Biotechnology

1.18USD+0.02 (+2.16%)

Price History

Full chart

Market Stats

Previous Close1.16
Open1.14
Day Range1.08 – 1.18
52-Week Range0.93 – 43.65
Volume74.17K
Market Cap16.94M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.87
Dividend Yield0.00%
50-Day Avg1.98
200-Day Avg3.17

About

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Imran Alibhai Ph.D.
  • Employees12
  • Headquarters3 Sugar Creek Center Boulevard, Sugar Land, TX, United States, 77478, USA
  • Websitehttps://tvarditherapeutics.com

Leadership

  • Dr. Imran Alibhai Ph.D.CEO & Director · b. 1976
  • Mr. Dan Conn J.D., M.B.A.CFO & Corporate Secretary · b. 1968
  • Dr. John Kauh M.D.Chief Medical Officer · b. 1974
  • Mr. David J. Tweardy M.D.Co-Founder & Scientific Advisory Board Member
  • Dr. Ronald A. DePinho M.D.Co-Founder & Chairman of Scientific Advisory Board · b. 1955
  • Dr. Michael T. Lewis Ph.D.Co-Founder & Scientific Advisory Board Member
  • Dr. Jeffrey Larson DABT, Ph.D.Senior Vice President of R&D · b. 1962
  • Mr. Stephen O'Brien CPAVP of Finance & Corporate Controller
  • Dr. Yixin Chen Ph.D.Vice President of CMC · b. 1961

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue135.08M23.03M41.87M20.97M7.14M0
Growth (%)--82.95%+81.81%-49.92%-65.96%-100.00%
Cost of Revenue-1.55M7.51M6.43M812.00K95.00K
Gross Profit-21.47M34.35M14.54M6.33M-95.00K
Gross Margin-93.25%82.05%69.32%88.62%-
Operating Expense-110.56M121.89M136.03M62.11M26.65M
Operating Income5.38M-89.08M-87.53M-121.50M-55.78M-26.75M
Operating Margin3.99%-386.85%-209.08%-579.43%-781.57%-
EBITDA8.73M-86.89M-83.80M-117.65M-62.60M-18.12M
EBITDA Margin6.47%-377.31%-200.17%-561.09%-877.12%-
Net Income8.41M-88.44M-85.47M-118.51M-70.87M-18.21M
Net Income Margin6.23%-384.06%-204.16%-565.21%-992.95%-
R&D107.74M82.58M91.76M108.38M32.76M18.01M
R&D as % of Total Revenue79.76%358.60%219.17%516.89%458.95%-
Interest Expense--3.00K08.47M-
Interest Expense % of Total Revenue--0.01%0.00%118.72%-

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets271.16M247.06M45.10M27.00M43.83M32.07M
Total Liabilities22.16M19.53M90.15M89.06M48.42M11.13M
Total Equity249.00M227.52M-45.05M-62.06M-4.59M20.95M
Cash31.68M13.45M21.49M22.92M37.90M20.73M
Total Debt5.28M3.67M2.37M368.00K44.45M201.00K
Net Debt-26.41M-9.78M-19.12M-22.55M6.54M-20.53M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.49M-60.09M-17.87M-92.08M-60.92M-23.50M
Investing Cash Flow-20.27M-4.75M-22.00M43.46M48.74M-10.08M
Financing Cash Flow39.14M46.61M4.00K38.15M-3.60M22.70M
Capital Expenditure349.00K39.00K50.00K2.38M1.05M0
Free Cash Flow-5.84M-60.13M-17.92M-94.45M-61.96M-23.50M
FCF to OCF106.36%100.06%100.28%102.58%101.72%100.00%

Earnings

Report DateMar 28, 2014May 13, 2014Aug 8, 2014Nov 11, 2014Mar 27, 2015May 13, 2015Aug 11, 2015Nov 10, 2015Mar 11, 2016May 6, 2016Aug 5, 2016Nov 4, 2016Mar 10, 2017May 5, 2017Aug 4, 2017Nov 3, 2017Mar 16, 2018May 10, 2018Aug 7, 2018Nov 6, 2018Mar 12, 2019May 7, 2019Aug 7, 2019Nov 5, 2019Feb 27, 2020May 11, 2020Aug 10, 2020Nov 9, 2020Feb 25, 2021May 10, 2021Aug 9, 2021Nov 8, 2021Mar 1, 2022May 9, 2022Aug 8, 2022Nov 7, 2022Mar 6, 2023May 15, 2023Aug 7, 2023Nov 13, 2023Mar 4, 2024May 13, 2024Aug 5, 2024Nov 29, 2024Feb 26, 2025May 13, 2025Aug 14, 2025Nov 13, 2025Mar 31, 2026May 8, 2026Aug 14, 2026Nov 12, 2026
EPS Estimate-------------------0.51-0.49-0.58-0.58-0.58-0.74-0.61-0.62-0.54-0.351.59-0.47-0.61-0.02-0.63-0.52-0.08-0.43-0.32-0.51-0.54-0.52-0.45-0.40-0.26-0.24-0.20-0.58-0.39-0.81-0.57-0.65-0.65-0.51
EPS Actual-22.83-7.78-5.80-10.37-6.59-7.40-8.96-6.75-12.59-14.12-17.25-15.23-28.98-29.28-10.38-13.75-15.64-18.47-0.52-0.51-0.52-0.56-0.58-0.74-0.61-0.62-0.54-0.351.59-0.47-0.61-0.02-0.63-0.52-0.08-0.43-0.56-0.49-0.58-0.52-0.59-0.56-0.27-8.19-5.21-0.500.51-0.59-0.78-0.73-0.69-
Surprise-------------------1.96%-4.08%10.34%3.45%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-75.00%3.92%-7.41%0.00%-31.11%-40.00%-3.85%-3312.25%-2548.70%13.79%230.77%27.16%-36.84%-12.31%-6.15%-
Timing---------------------------------------------After-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-market

Key Statistics & Ratios

Market Cap16.94M
Enterprise Value1.79M
Trailing P/E0.00
Forward P/E0.00
Price / Sales559.61
Price / Book2.08
EPS-2.87
Book Value1.55
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-27.11M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-126.19%
Return on Assets-55.51%
Shares Outstanding13.34M
Shares Float9.63M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 9.25
  • Strong Buy
    4

Ownership Breakdown

Institutions
17.33%
Insiders
24.36%
Retail / Other
58.31%

Top Institutional Holders

  • Slate Path Capital LP
    704.12K5.28%
  • BlackRock Inc
    388.07K2.91%
  • Vanguard Capital Management, LLC
    344.71K2.58%
  • American Financial Group Inc
    223.66K1.68%
  • Geode Capital Management, LLC
    182.34K1.37%
  • Silvercrest Asset Management Group LLC
    101.03K0.76%
  • State Street Corp
    97.23K0.73%
  • Renaissance Technologies Corp
    92.10K0.69%
  • Morgan Stanley - Brokerage Accounts
    72.89K0.55%
  • UBS Group AG
    50.45K0.38%
  • Northern Trust Corp
    49.08K0.37%
  • Vanguard Fiduciary Trust Co
    46.87K0.35%
  • AQR Capital Management LLC
    42.19K0.32%
  • Vanguard Portfolio Management, LLC
    33.83K0.25%
  • Squarepoint Ops LLC
    32.68K0.24%
  • The Goldman Sachs Group Inc
    23.90K0.18%
  • Farallon Capital Management, L.L.C.
    21.44K0.16%
  • GSA Capital Partners LLP
    17.89K0.13%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    258.43K1.94%
  • Fidelity Extended Market Index
    42.12K0.32%

Stock Splits

  • Apr 16, 20251:3
  • Dec 31, 20241:12